Drugs & Targets C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan March 03, 2023Vol.49 No.09
Drugs & Targets HRA Pharma & Celnova Pharma partner to launch medicines in South America for adrenocortical carcinoma March 03, 2023Vol.49 No.09
Drugs & Targets Gritstone bio and NCI collaborate to evaluate neoantigen cell therapy + vaccine for mutant KRAS solid tumors February 17, 2023Vol.49 No.07
Drugs & Targets MD Anderson and Xilis collaborate on preclinical research February 17, 2023Vol.49 No.07
Drugs & Targets FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer February 10, 2023Vol.49 No.06
Drugs & Targets St. John’s Cancer Institute, Absci partner to expedite cancer therapy development February 10, 2023Vol.49 No.06
Drugs & Targets Jaypirca receives FDA accelerated approval for R/R mantle cell lymphoma February 03, 2023Vol.49 No.05
Drugs & Targets Orserdu & companion diagnostic for ER+, HER2-, ESR1-mutated advanced breast cancer receive FDA approval February 03, 2023Vol.49 No.05
Drugs & Targets RefleXion receives FDA clearance for SCINTIX biology-guided radiotherapy February 03, 2023Vol.49 No.05
Drugs & Targets FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma February 03, 2023Vol.49 No.05
